PMC:2193592 / 3254-4593 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/2193592","sourcedb":"PMC","sourceid":"2193592","source_url":"http://www.ncbi.nlm.nih.gov/pmc/2193592","text":"Antibodies and Blocking Reagents.\nAntibodies used for flow cytometry were: anti-CD86-FITC, -CD83-PE, -HLA-DR-PerCP, -CD69-FITC or -PE, -CD25-FITC, -CD3-FITC or -PE, -CD19-FITC, -CD14-FITC, -CD1a-FITC, -CD80-FITC or -PE, and -CD56-FITC or -PE (Becton Dickinson). Staining of cells was performed according to standard protocols and flow cytometric analysis was performed using a FACSCalibur™ cytometer. Antibodies used for magnetic activated cell sorting (MACS®) and subset purifications were: anti-CD3, anti-CD14, and anti-CD19 (Becton Dickinson). Blocking/neutralizing reagents used in different experiments were: anti–IFN-α (mAb MMHA-1 and sheep polyclonal anti–human; Ancell); anti–IFN-β (sheep polyclonal anti–human; Biosource International); r-hu-fas-ligand/Fc chimera (CD178; R\u0026D Systems); hu-CTLA-4 muIg fusion protein (CD152; Ancell); anti–LFA-1 (CD11a, mAb G43–25B; Becton Dickinson); anti–TNF-α (mAb B154.2); anti–IL-12 p40 (mAb C8.6); and anti–IFN-γ (mAb B133.3) (all provided by G. Trinchieri, Schering Plough Corp., Lyon, France); humanized anti-CD40 (mAb 5H7; supplied by K. Chu, Chiron Corp., Emeryville, CA). All neutralizing antibodies and reagents were used at, at least, two different concentrations which were equal to and exceeded the manufacturers' instructions or their previously published levels for neutralization.","divisions":[{"label":"Title","span":{"begin":0,"end":33}}],"tracks":[]}